Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Cancer Prev Res (Phila). 2016 Jan 26;9(4):317–323. doi: 10.1158/1940-6207.CAPR-15-0033

Table 2.

Glycan features from the discovery sample set meeting performance criteriaa for test set evaluation, together with their putative structure, and median, AUC and P-value in both the discovery and test sample sets.

Glycan Glycan
Feature		 Glycan
variablea 		Discovery Test
NSCLC
(median,
N=98)		 Control

(median,
N=194)		 AUC P-valueb FDR pAUC(0.10)c NSCLC

(median, N=108)		 Control
(median,
N=216)		 AUC P-valueb FDR
X Gal_1 −6.34E-02 2.46E-02 0.66 >0.001 0.017 6.43E-06 −7.06E-02 9.24E-03 0.61 1.06E-03 0.007
X Gal_3 −3.42E-02 1.89E-02 0.66 0.001 0.014 1.35E-05 −6.18E-02 1.57E-02 0.61 1.65E-03 0.007
X Gal_4 −7.05E-02 1.50E-02 0.65 0.001 0.015 1.97E-05 −7.42E-02 3.78E-02 0.58 1.56E-02 0.040
X Gal_5 −7.64E-02 1.59E-02 0.65 0.001 0.011 2.37E-05 −1.21E-01 3.67E-02 0.54 1.94E-01 0.195
X Sia_2 2.85E+00 −9.04E-01 0.65 0.001 0.009 2.59E-05 1.51E+00 −2.77E-01 0.57 4.34E-02 0.056
X H6N5F1 −4.40E-05 2.20E-05 0.64 0.001 0.007 6.71E-05 −1.30E-05 1.60E-07 0.57 3.17E-02 0.056
X Sia_1 5.05E+01 −1.02E+01 0.64 0.002 0.006 1.54E-04 2.10E+01 −4.51E+00 0.58 1.85E-02 0.040
X Tr 5.80E-03 −2.23E-03 0.63 0.004 0.013 2.73E-04 6.27E-03 −1.18E-05 0.57 4.21E-02 0.056
X Gal_2 −1.56E-01 5.63E-02 0.63 0.005 0.012 3.84E-04 −1.17E-01 2.15E-02 0.60 2.45E-03 0.008
X H5N4F1 −1.30E-03 4.90E-04 0.62 0.005 0.006 5.40E-04 −2.00E-03 1.20E-03 0.64 3.61E-05 >0.001
X H3N4F1 3.20E-03 −1.50E-03 0.61 0.010 0.014 1.38E-03 3.10E-03 −8.70E-04 0.56 6.86E-02 0.081
X H3N4 6.70E-04 −1.40E-04 0.60 0.025 0.009 3.82E-03 5.90E-04 −2.00E-03 0.54 1.95E-01 0.195
a

Glycan variables identified for testing were those with AUC>0.60 and an FDR <0.05.

b

p-value calculated using the Wilcoxon test.

c

Partial AUC (pAUC) associated with a false positive rate (FPR) upper bound of 0.10 (i.e., area under the curve for the FPR range of 0–0.10)